San Francisco, CA, United States of America

Kenneth Charles Fang

USPTO Granted Patents = 11 

 

Average Co-Inventor Count = 3.3

ph-index = 4

Forward Citations = 50(Granted Patents)


Location History:

  • Neihu District, Taipei City, TW (2010)
  • San Francisco, CA (US) (2015 - 2024)

Company Filing History:


Years Active: 2010-2025

Loading Chart...
Loading Chart...
11 patents (USPTO):Explore Patents

Title: Innovations in Lung Cancer Diagnosis by Kenneth Charles Fang

Introduction

Kenneth Charles Fang, an accomplished inventor based in San Francisco, CA, has made significant contributions to the field of medical diagnostics. With a remarkable portfolio of 11 patents, his work focuses primarily on the detection and classification of lung cancer through innovative methods involving biomarker proteins.

Latest Patents

Among Kenneth's most notable inventions are his recent patents related to compositions, methods, and kits for the diagnosis of lung cancer. These patents detail methods for identifying biomarker proteins showcasing differential expression in individuals with various lung conditions compared to healthy subjects. The inventions aim to provide reliable diagnostic tools that can distinguish between lung cancer types, including malignant versus benign tumors and subtypes such as Small Cell Lung Cancer (SCLC) and Non-Small Cell Lung Cancer (NSCLC). The compositions and methods are designed not only to diagnose lung cancer but also to monitor and classify various lung conditions effectively.

Career Highlights

Kenneth has demonstrated his expertise through his work with notable companies such as Biodesix, Inc. and Integrated Diagnostics, Inc. His innovations have the potential to revolutionize lung cancer diagnosis, providing healthcare providers with more accurate tools to classify and monitor patient conditions.

Collaborations

Throughout his career, Kenneth has collaborated with prominent colleagues in the field, including Paul Edward Kearney and Xiao-Jun Li. These partnerships have likely enhanced the scope and impact of his inventions, contributing to advancements in lung cancer diagnostics.

Conclusion

Kenneth Charles Fang is a pioneering inventor whose innovative solutions are shaping the future of lung cancer diagnosis. His dedicated work in understanding biomarker proteins provides a pathway for more accurate and efficient medical assessments, ultimately benefiting patients and healthcare professionals alike. With his growing portfolio of patents, Kenneth continues to be a significant figure in the domain of medical diagnostics.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…